XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
OPERATING ACTIVITIES    
Net Income (Loss) $ (29,745) $ (57,388)
Non-cash items:    
Depreciation 352 1,047
Loss on impairment of leasehold improvements and lab equipment 2,811 167
Stock-based compensation expense 5,691 7,354
Change in fair value of contingent consideration 827 735
Non-cash royalty revenue (1,223) (1,736)
Non-cash interest expense 78 98
Net accretion and amortization of investments in marketable securities (1,927) (2,212)
Net change in operating items:    
Accounts receivable 1,504 168
Prepaid expenses and other assets 400 1,145
Accounts payable and accrued liabilities (2,911) (2,727)
Change in deferred license revenue (10,434) (880)
Other liabilities (380) (306)
Net cash used in operating activities (34,957) (54,535)
INVESTING ACTIVITIES    
Purchase of investments in marketable securities (114,514) (98,318)
Proceeds from sale of property and equipment 9 0
Disposition of investments in marketable securities 131,446 107,951
Acquisition of property and equipment 0 (96)
Net cash provided by investing activities 16,941 9,537
FINANCING ACTIVITIES    
Issuance of common shares pursuant to the Open Market Sale Agreement 0 44,124
Issuance of common shares pursuant to exercise of stock options 3,900 6,055
Issuance of common shares pursuant to ESPP 181 396
Net cash provided by financing activities 4,081 50,575
Effect of foreign exchange rate changes on cash and cash equivalents 13 (16)
(Decrease) / Increase in cash and cash equivalents (13,922) 5,561
Cash and cash equivalents, beginning of period 36,330 26,285
Cash and cash equivalents, end of period $ 22,408 $ 31,846